These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 28947304)

  • 1. Comparison of the EORTC tables and the EAU categories for risk stratification of patients with nonmuscle-invasive bladder cancer.
    Rieken M; Shariat SF; Kluth L; Crivelli JJ; Abufaraj M; Foerster B; Mari A; Ilijazi D; Karakiewicz PI; Babjuk M; Gönen M; Xylinas E
    Urol Oncol; 2018 Jan; 36(1):8.e17-8.e24. PubMed ID: 28947304
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Validation of EORTC, CUETO, and EAU risk stratification in prediction of recurrence, progression, and death of patients with initially non-muscle-invasive bladder cancer (NMIBC): A cohort analysis.
    Jobczyk M; Stawiski K; Fendler W; Różański W
    Cancer Med; 2020 Jun; 9(11):4014-4025. PubMed ID: 32216043
    [TBL] [Abstract][Full Text] [Related]  

  • 3. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Risk Stratification Tools and Prognostic Models in Non-muscle-invasive Bladder Cancer: A Critical Assessment from the European Association of Urology Non-muscle-invasive Bladder Cancer Guidelines Panel.
    Soukup V; Čapoun O; Cohen D; Hernández V; Burger M; Compérat E; Gontero P; Lam T; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Yuan Y; Zigeuner R; Babjuk M
    Eur Urol Focus; 2020 May; 6(3):479-489. PubMed ID: 30470647
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Accuracy of the EORTC risk tables and of the CUETO scoring model to predict outcomes in non-muscle-invasive urothelial carcinoma of the bladder.
    Xylinas E; Kent M; Kluth L; Pycha A; Comploj E; Svatek RS; Lotan Y; Trinh QD; Karakiewicz PI; Holmang S; Scherr DS; Zerbib M; Vickers AJ; Shariat SF
    Br J Cancer; 2013 Sep; 109(6):1460-6. PubMed ID: 23982601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. EORTC risk tables are more suitable for Chinese patients with nonmuscle-invasive bladder cancer than AUA risk stratification.
    Wang H; Ding W; Jiang G; Gou Y; Sun C; Chen Z; Xu K; Xia G
    Medicine (Baltimore); 2018 Sep; 97(36):e12006. PubMed ID: 30200080
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term cancer-specific outcomes of TaG1 urothelial carcinoma of the bladder.
    Rieken M; Xylinas E; Kluth L; Crivelli JJ; Chrystal J; Faison T; Lotan Y; Karakiewicz PI; Holmäng S; Babjuk M; Fajkovic H; Seitz C; Klatte T; Pycha A; Bachmann A; Scherr DS; Shariat SF
    Eur Urol; 2014 Jan; 65(1):201-9. PubMed ID: 23998688
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of expected treatment outcomes, obtained using risk models and international guidelines, with observed treatment outcomes in a Dutch cohort of patients with non-muscle-invasive bladder cancer treated with intravesical chemotherapy.
    Lammers RJ; Palou J; Witjes WP; Janzing-Pastors MH; Caris CT; Witjes JA
    BJU Int; 2014 Aug; 114(2):193-201. PubMed ID: 24304638
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Efficacy of European Organization for Research and Treatment of Cancer (EORTC) risk tables for the prediction of recurrence and progression of non-muscle invasive bladder cancer after intravesical pirarubicin instillation].
    Xu C; Jiang XZ; Zhang NZ; Ma L; Xu ZS
    Zhonghua Zhong Liu Za Zhi; 2012 Aug; 34(8):609-12. PubMed ID: 23158996
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The efficiency of the EORTC scoring system for the prediction of recurrence and progression of non-muscle-invasive bladder cancer treated by bacillus Calmette-Guerin immunotherapy.
    Ajili F; Darouiche A; Chebil M; Boubaker S
    Ultrastruct Pathol; 2013 Aug; 37(4):249-53. PubMed ID: 23899093
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ki-67 is an independent indicator in non-muscle invasive bladder cancer (NMIBC); combination of EORTC risk scores and Ki-67 expression could improve the risk stratification of NMIBC.
    Ding W; Gou Y; Sun C; Xia G; Wang H; Chen Z; Tan J; Xu K; Qiang D
    Urol Oncol; 2014 Jan; 32(1):42.e13-9. PubMed ID: 24360660
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The efficacy of the EORTC scoring system and risk tables for the prediction of recurrence and progression of non-muscle-invasive bladder cancer after intravesical bacillus calmette-guerin instillation.
    Seo KW; Kim BH; Park CH; Kim CI; Chang HS
    Korean J Urol; 2010 Mar; 51(3):165-70. PubMed ID: 20414391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accuracy of the CUETO, EORTC 2016 and EAU 2021 scoring models and risk stratification tables to predict outcomes in high-grade non-muscle-invasive urothelial bladder cancer.
    Krajewski W; Aumatell J; Subiela JD; Nowak Ł; Tukiendorf A; Moschini M; Basile G; Poletajew S; Małkiewicz B; Del Giudice F; Maggi M; Chung BI; Cimadamore A; Galosi AB; Fave RFD; D'Andrea D; Shariat SF; Hornak J; Babjuk M; Chorbińska J; Teoh JY; Muilwijk T; Joniau S; Tafuri A; Antonelli A; Panunzio A; Alvarez-Maestro M; Simone G; Mastroianni R; Łaszkiewicz J; Lonati C; Zamboni S; Simeone C; Niedziela Ł; Candela L; Macek P; Contieri R; Hidalgo BG; Rivas JG; Sosnowski R; Mori K; Mir C; Soria F; González-Padilla DA; Faba ÒR; Palou J; Ploussard G; Rajwa P; Hałoń A; Laukhtina E; Pradere B; Tully K; Burgos FJ; Cidre MÁJ; Szydełko T;
    Urol Oncol; 2022 Nov; 40(11):491.e11-491.e19. PubMed ID: 35851185
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Can re-cTURBT be useful in pT1HG disease as a risk indicator of recurrence and progression? A single centre experience.
    Giulianelli R; Gentile BC; Mirabile G; Albanesi L; Tariciotti P; Rizzo G; Buscarini M; Vermiglio M
    Arch Ital Urol Androl; 2017 Dec; 89(4):272-276. PubMed ID: 29473376
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Risk-based Management of Non-muscle Invasive Bladder Cancer: Experience from Tribhuvan University Teaching Hospital.
    Luitel BR; Chalise PR; Nathani S; Gupta DK; Subedi P; Chapagain S; Sharma UK; Gyawali PR; Shrestha GK; Joshi BR
    Kathmandu Univ Med J (KUMJ); 2016 Oct.-Dec.; 14(56):352-356. PubMed ID: 29371493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cell-cycle markers do not improve discrimination of EORTC and CUETO risk models in predicting recurrence and progression of non-muscle-invasive high-grade bladder cancer.
    Passoni N; Gayed B; Kapur P; Sagalowsky AI; Shariat SF; Lotan Y
    Urol Oncol; 2016 Nov; 34(11):485.e7-485.e14. PubMed ID: 27637323
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The EORTC tables overestimate the risk of recurrence and progression in patients with non-muscle-invasive bladder cancer treated with bacillus Calmette-Guérin: external validation of the EORTC risk tables.
    Fernandez-Gomez J; Madero R; Solsona E; Unda M; Martinez-Piñeiro L; Ojea A; Portillo J; Montesinos M; Gonzalez M; Pertusa C; Rodriguez-Molina J; Camacho JE; Rabadan M; Astobieta A; Isorna S; Muntañola P; Gimeno A; Blas M; Martinez-Piñeiro JA;
    Eur Urol; 2011 Sep; 60(3):423-30. PubMed ID: 21621906
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Comparison of EORTC And CUETO Risk Tables in Terms of the Prediction of Recurrence and Progression in All Non-Muscle-Invasive Bladder Cancer Patients.
    Dalkilic A; Bayar G; Kilinc MF
    Urol J; 2019 Feb; 16(1):37-43. PubMed ID: 30120763
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Value of European Organisation for Research and Treatment of Cancer score system for predication of immediate postoperative intravesical instillation of pirarubicin after transurethral resection of non-muscle invasive bladder cancer].
    Ding XL; Yang DL; Yan RP; Li ZP; Ye CW; He J; Yu L; He SC; Li HD
    Zhonghua Zhong Liu Za Zhi; 2018 Apr; 40(4):308-312. PubMed ID: 29730921
    [No Abstract]   [Full Text] [Related]  

  • 20. Recurrence and progression in non-muscle-invasive bladder cancer using EORTC risk tables.
    Altieri VM; Castellucci R; Palumbo P; Verratti V; Sut M; Olivieri R; Manco R; Ricciardulli S; Nicolai M; Criniti P; Tenaglia RL
    Urol Int; 2012; 89(1):61-6. PubMed ID: 22722366
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.